Abstract Details

Title Understanding the Experiences of Patients and Dyad Care Partners in Early Alzheimer’s Disease

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) P11 - Poster Session 11 (8:00 AM-9:00 AM)

Poster/Presentation
Number 3-011

Objective To explore and compare patient-care partner dyad experiences in early Alzheimer’s Disease (AD) including symptoms, economic and emotional burden, and treatment preferences.

Background Understanding the experience of patients and their care partners in early AD is crucial for identifying unmet needs in disease management and determining necessary support systems during this critical period for emerging disease-modifying therapies.

Design/Methods Adult patients with early AD and their care partners completed a 25-minute quantitative online survey to describe symptoms, emotional and financial burden and treatment perspectives. Survey content was informed by learnings from qualitative interviews and social media listening. Data were analyzed descriptively and comparatively using statistical pairing tests.

Results Survey respondents included 150 patients (female: 55%, Mean [range] age: 70.8 [55-91]) and their dyad care partners (female: 74%, Mean [range] age: 52.6 [21-97]). Typically, care partners were patients' partner/spouse (33%) or son/daughter (27%). Most frequent patient-reported difficulties were misplacing/losing belongings (68%) and difficulty concentrating (35%). These difficulties were reported by significantly more care partners than patients (p<0.05). Both groups (63% patients, 65% care partners) reported negative impacts on their emotional wellbeing. Patients more frequently reported impacts on their financial wellbeing than care partners, however employed patients and care partners reported similar levels of impact on their work or studies. About half of patients (52%) were not currently receiving any AD treatment. Stopping/slowing disease progression (84% patients, 91% care partners), improving symptoms (81% patients, 85% care partners) and side effect risk (68% patients, 76% care partners) were the most important future treatment considerations, and daily oral treatment was the most preferred treatment administration method by both groups (66% patients, 63% care partners).

Conclusions Early AD greatly impacts patients and care partners, with some differences in care partner perceptions and patient experiences of key symptoms and overall, emotional and financial impacts. These considerations can inform future treatment approaches.

Authors/Disclosures
Lei Lv, PhD PRESENTER	Dr. Lv has received personal compensation for serving as an employee of Novo Nordisk .
Elnara Fazio-Eynullayeva (NNI)	Ms. Fazio-Eynullayeva has received personal compensation for serving as an employee of Novo Nordisk. Ms. Fazio-Eynullayeva has stock in Novo Nordisk.
Paul Mystkowski, MD (Novo Nordisk)	Dr. Mystkowski has received personal compensation for serving as an employee of Novo Nordisk. Dr. Mystkowski has stock in Novo Nordisk.
Caroline McKay, PhD	Dr. McKay has received personal compensation for serving as an employee of Novo Nordisk. Dr. McKay has stock in Novo Nordisk. Dr. McKay has stock in Takeda. Dr. McKay has stock in Johnson & Johnson. Dr. McKay has stock in Merck.
Jordan Miller, PhD	Dr. Miller has nothing to disclose.
Stephanie McKee	Ms. McKee has received personal compensation for serving as an employee of Clarivate . Ms. McKee has stock in Clarivate .
Tamara Al-zubeidi, BSc	Mrs. Al-zubeidi has received personal compensation for serving as an employee of Clarivate. Mrs. Al-zubeidi has stock in Clarivate analytics .
Catherine J. Bottomley, PhD	Dr. Bottomley has received personal compensation for serving as an employee of Clarivate. Dr. Bottomley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Otsuka Pharmaceutical. An immediate family member of Dr. Bottomley has received personal compensation in the range of $0-$499 for serving as a Consultant for Guidepoint Consulting. Dr. Bottomley has stock in Clarivate Analytics. The institution of an immediate family member of Dr. Bottomley has received research support from Skin Microbiome in Healthy Aging Consortium. The institution of an immediate family member of Dr. Bottomley has received research support from British Skin Foundation. Dr. Bottomley has received intellectual property interests from a discovery or technology relating to health care.
Catherine M. Floegel	Ms. Floegel has received personal compensation for serving as an employee of Clarivate. Ms. Floegel has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Clarivate .
Richard Hyde	Mr. Hyde has received personal compensation for serving as an employee of Clarivate.
Abdalla A. Aly, PhD	Dr. Aly has received personal compensation for serving as an employee of Novo Nordisk Incorporated. Dr. Aly has stock in Novo Nordisk Incorporated.

��ɫ��

��ɫ��